Need For Forums

The failure of scientific journals to offer a forum for the dissemination of hypotheses and theories in biomedical science is a serious problem, as argued eloquently by David Horrobin [Opinion: "Discouraging Hypotheses Slows Progress," The Scientist, Nov. 26, 1990, page 13]. It is unfortunate that it is now so difficult to publish suggestive ideas. While Medical Hypotheses is one approach to solving this problem, I would like to encourage editors of other journals to consider another possibili

Written byStephen Harvey
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

It is unfortunate that it is now so difficult to publish suggestive ideas. While Medical Hypotheses is one approach to solving this problem, I would like to encourage editors of other journals to consider another possibility. When a senior author has demonstrated his or her scientific credentials by the publication of two or three papers in a journal, he or she could be given the opportunity to publish a hypothesis or theory, subject to certain restrictions, such as the three criteria Horrobin suggests.

Such articles would be subjected to a brief review, to be certain that they are clearly written and meet the journal's criteria for publication. I strongly agree with Horrobin that journals should not worry about whether such ideas are "right." As long as they stimulate thinking and suggest new experiments, hypotheses belong in the literature, where they reach a wide audience.

For a very modest increase in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies